Noema Pharma’s CHF 54 Million Series A Financing


Walder Wyss advised Gilde Healthcare Partners, Polaris Partners, Invus Capital and BioMedInvest as investors on the financing. Vischer advised Noema Pharma.

Noema Pharma, a Swiss clinical-stage company targeting orphan neurological disorders, concluded an oversubscribed Series A financing round, raising CHF54 million to fund further development of its promising clinical-stage pipeline.

The round was co-led by Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan, and Polaris Partners, a healthcare and technology investment firm based in the United States. The global consortium of new international investors includes Gilde Healthcare, Invus and BioMed Partners. Roche, the Swiss multinational healthcare company, received a shareholding in Noema in exchange for rights to four clinical-stage product-candidates.

Proceeds from the financing will be used to advance the development of four clinical-stage product candidates.

The Walder Wyss team included Alexander Gutmans (Picture), Robert von Rosen, Markus R. Frick and Karina Tschon.

The Vischer team included Matthias Staehelin, Christian Wyss Nadia Tarolli Schmidt, Vincent S. Reardon and Pauline Pfirter.

Involved fees earner: Pauline Pfirter – VISCHER AG; Vincent Reardon – VISCHER AG; Matthias Staehelin – VISCHER AG; Nadia Tarolli – VISCHER AG; Christian Wyss – VISCHER AG; Markus Frick – Walder Wyss Ltd.; Alexander Gutmans – Walder Wyss Ltd.; Karina Tschon – Walder Wyss Ltd.; Robert von Rosen – Walder Wyss Ltd.;

Law Firms: VISCHER AG; Walder Wyss Ltd.;

Clients: BioMedPartners AG; Gilde Healthcare; Invus; Noema Pharma; Polaris Partners;

Print Friendly, PDF & Email